Compare RAYMED LABS. with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

RAYMED LABS vs MESCO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    RAYMED LABS MESCO PHARMA RAYMED LABS/
MESCO PHARMA
 
P/E (TTM) x -5.4 -1,759.8 - View Chart
P/BV x - - - View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 RAYMED LABS   MESCO PHARMA
EQUITY SHARE DATA
    RAYMED LABS
Mar-20
MESCO PHARMA
Mar-20
RAYMED LABS/
MESCO PHARMA
5-Yr Chart
Click to enlarge
High Rs312 24.5%   
Low Rs19 10.6%   
Sales per share (Unadj.) Rs00-  
Earnings per share (Unadj.) Rs-0.10 271.9%  
Cash flow per share (Unadj.) Rs-0.10 242.8%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs-4.6-5.4 85.7%  
Shares outstanding (eoy) m4.2720.32 21.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio xNMNM-  
Avg P/E ratio x-14.8-216.2 6.8%  
P/CF ratio (eoy) x-16.6-216.2 7.7%  
Price / Book Value ratio x-0.4-1.9 21.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m8212 3.9%   
No. of employees `000NANA-   
Total wages/salary Rs m00-   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m00-  
Other income Rs m00-   
Total revenues Rs m00-   
Gross profit Rs m-1-1 64.3%  
Depreciation Rs m00-   
Interest Rs m00-   
Profit before tax Rs m-1-1 57.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m00-   
Profit after tax Rs m-1-1 57.1%  
Gross profit margin %NMNM- 
Effective tax rate %00-   
Net profit margin %NMNM- 
BALANCE SHEET DATA
Current assets Rs m10 230.8%   
Current liabilities Rs m220 14,940.0%   
Net working cap to sales %NMNM- 
Current ratio x02.6 1.5%  
Inventory Days DaysNMNM- 
Debtors Days DaysNMNM- 
Net fixed assets Rs m22 92.8%   
Share capital Rs m43197 21.7%   
"Free" reserves Rs m-63-308 20.4%   
Net worth Rs m-20-110 18.0%   
Long term debt Rs m0112 0.0%   
Total assets Rs m32 117.4%  
Interest coverage xNMNM-  
Debt to equity ratio x0-1.0 0.0%  
Sales to assets ratio x00-   
Return on assets %-21.7-44.9 48.3%  
Return on equity %2.80.9 314.4%  
Return on capital %2.8-48.0 -5.9%  
Exports to sales %NMNM-  
Imports to sales %NMNM-  
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m00-   
Fx outflow Rs m00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m0-1 0.0%  
From Investments Rs mNANA-  
From Financial Activity Rs mNA1 0.0%  
Net Cashflow Rs m00 0.0%  

Share Holding

Indian Promoters % 28.4 39.3 72.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 71.6 60.7 118.0%  
Shareholders   1,428 40,823 3.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare RAYMED LABS With:   SAKAR HEALTHCARE   PANACEA BIOTECH  JENBURKT PH.  SUVEN PHARMACEUTICALS  OMKAR PHARMACHEM  



Today's Market

4 Reasons Why Sensex Surged 1,016 Points Today(Closing)

Indian share markets continued their momentum and ended their day on a strong note today.

Related Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

6 Penny Stocks that Rallied 1,000%+ in One Year(Views On News)

Dec 6, 2021

These penny stocks shed their penny status by surging 1,000% or more in the last one year.

The Biggest Winners and Losers in India's Transition to Electric Vehicles(Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

RAYMED LABS SHARE PRICE


Dec 6, 2021 (Close)

TRACK RAYMED LABS

  • Track your investment in RAYMED LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RAYMED LABS 5-YR ANALYSIS

COMPARE RAYMED LABS WITH

MARKET STATS